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Pretreatment High MCV as Adverse Prognostic Marker in Nonanemic
Patients with Head and Neck Cancer
Daniele Borsetto, MD ; Jerry Polesel, ScD ; Giancarlo Tirelli, MD; Anna Menegaldo, MD;
Vittorio Baggio, MD; Alessandro Gava, MD; Paul Nankivell, PhD; Paul Pracy, FRCS;
Jonathan Fussey, FRCS (ORL-HNS); Paolo Boscolo-Rizzo, MD
Objective: Mean corpuscular volume (MCV) has been shown in to be a reliable prognostic marker in other cancers; how-
ever, no evidence exists on its use in head and neck squamous cell carcinoma (HNSCC). This study aimed to investigate the
association between MCV, hemoglobin, platelet count and albumin concentration, and survival in stage III/IVA-B HNSCC treated
with concurrent chemoradiotherapy.
Study Design: Retrospective cohort study.
Methods: In this multicenter retrospective study, we analyzed MCV, platelet count, hemoglobin concentration, and albumin
concentration in peripheral blood samples from 260 patients with HNSCC undergoing organ preservation treatment with curative
intent at the time of diagnosis. We then analyzed survival outcomes after accounting for confounders using multivariate analysis.
Results: After adjustment for potential confounders, patients with low hemoglobin had a 3.3-fold higher risk of death
(95% confidence interval [CI]: 2.26-4.81) than those with normal hemoglobin. Patients with an elevated MCV had a 1.54-fold
higher risk of death (95% CI: 1.06-2.24), independent of site, stage, and human papillomavirus status. Interestingly, the effect
of MCV on overall and progression-free survival was limited to those with a normal pretreatment hemoglobin. We identified
no associations between pretreatment platelet count or albumin concentration and survival.
Conclusion: These findings suggest that pretreatment anemia and macrocytosis are independent predictors of lower
overall and progression-free survival in HNSCC patients undergoing organ preservation treatment.
Key Words: Mean corpuscular volume, Head and neck squamous cell carcinoma, macrocytic anemia, platelets, HPV,
prognosis.
Level of Evidence: III
Laryngoscope, 00:1–8, 2020
INTRODUCTION
Head and neck squamous cell carcinoma (HNSCC) is
a potentially lethal cancer that develops in the mucosal
epithelium of the oral cavity, hypopharynx, oropharynx,
or larynx. It is estimated that HNSCC will affect 151
thousand new patients in Europe and approximately 833
thousand worldwide in 2020, thus representing 4% and
5% of all new cancers, respectively.1 HNSCC is more com-
mon in men and in those aged over 60 years.1 Tobacco
and alcohol use represent the main risk factors for
HNSCC, with a synergistic effect.2 To date, traditional
tumor-based histopathological risk factors such as tumor
and lymph node staging, tumor differentiation, and sta-
tus of resection margin remain the only clinical prognos-
tic factors available.
Recent findings have shown hematological parame-
ters to be predictive markers for patients with other types
of cancer. Mean corpuscular volume (MCV) is a measure
of the average volume of red blood cells, and as well as
being an indicator of folate and vitamin B12 deficiency,
elevated MCV has been linked to the incidence of several
cancers. In addition, recent studies have found an associ-
ation between high MCV and the prognosis of colorectal,
esophageal, and liver cancers.3–5
In the last decade, platelet activation has been found
to be an important step in the process of carcinogenesis
and metastasis.6 Platelet count (PLT) reflects platelet
activation, and patients with thrombocytosis have been
reported to have a worse prognosis in multiple solid
tumors, such as ovarian cancer,7 endometrial cancer,8
gastric cancer,9 and colorectal cancer.10
Furthermore, anemia, and particularly
nonmicrocytic anemia, is associated with poorer cancer-
This is an open access article under the terms of the Creative
Commons Attribution-NonCommercial-NoDerivs License, which permits
use and distribution in any medium, provided the original work is prop-
erly cited, the use is non-commercial and no modifications or adaptations
are made.
From the Department of ENT/Head and Neck Surgery (D.B., P.N.,
P.P., J.F.), Queen Elizabeth University Hospital Birmingham,
Birmingham, UK; Unit of Cancer Epidemiology (J.P.), Centro di
Riferimento Oncologico di Aviano (CRO) IRCCS, Aviano, Italy; ENT
Clinic, Head and Neck Department (G.T.), Azienda Sanitaria
Universitaria Integrata di Trieste, Trieste, Italy; Department of
Neurosciences, Section of Otolaryngology (A.M., P.B.-R.), University of
Padova, Treviso, Italy; Department of Radiation Oncology (V.B., A.G.),
Treviso Regional Hospital, Treviso, Italy; and theInstitue of Cancer and
Genomic Sciences (P.N.), University of Birmingham, Birmingham, UK.
Editor’s Note: This Manuscript was accepted for publication on
June 02, 2020.
The authors have no funding, financial relationships, or conflicts of
interest to disclose.
Send correspondence to Daniele Borsetto, MD, Queen Elizabeth
University Hospital, Birmingham, Mindelsohn Way, Birmingham, B15
2TH, UK. E-mail: daniele.borsetto@gmail.com
DOI: 10.1002/lary.28882
Laryngoscope 00: 2020 Borsetto et al.: Mean Corpuscular Volume as Marker in HNSCCs
1
The Laryngoscope
© 2020 The Authors. The Laryngoscope
published by Wiley Periodicals, Inc. on
behalf of The American Laryngological,
Rhinological and Otological Society, Inc.
TABLE I.
Median Values and Interquartile Rage (Q1-Q3) of Hemoglobin, Mean Corpuscular Value, Platelets, and Albumin According to
Sociodemographic and Clinical Characteristics.*
n Hb (g/dL) MCV (fL) Platelets (103/mm3) Albumin (g/dL)
Overall 260 13.8 (12.6–14.8) 93.1 (89.8–98.7) 258 (209–317) 4.4 (4.1–4.7)
Gender
Male 200 13.9 (12.7–15.0) 94.2 (90.7–99.5) 259 (210–308) 4.4 (4.1–4.7)
Female 60 13.4 (12.2–14.0) 91.6 (89.1–94.3) 256 (208–339) 4.5 (4.4–4.7)
P = .016 P = .002 P = .560 P = .160
Age (yrs)
< 60 119 13.8 (12.6–14.9) 93.8 (89.4–99.4) 275 (206–339) 4.4 (4.1–4.6)
60–69 96 13.8 (12.6–15.0) 93.2 (90.5–98.3) 247 (211–314) 4.5 (4.2–4.7)
≥ 70 45 13.5 (12.6–14.0) 92.3 (89.4–97.7) 240 (212–186) 4.4 (4.2–4.6)
P = .429 P = .558 P = .176 P = .148
Tobacco smoking
Never 29 14.1 (13.4–15.1) 89.1 (87.1–92.9) 220 (201–279) 4.6 (4.1–4.7)
Ever 209 13.6 (12.5–14.5) 94.2 (91.0–99.6) 262 (213–325) 4.4 (4.1–4.7)
Unknown 22 14.3 (12.6–15.4) 92.3 (89.1–93.9) 277 (181–315) 4.4 (4.0–4.7)
P = .031 P < .001 P = .129 P = .215
Alcohol drinking
Never 42 13.5 (12.2–14.6) 90.0 (86.4–94.7) 240 (207–299) 4.3 (3.9–4.5)
Ever 196 13.8 (12.7–14.8) 94.2 (91.1–99.6) 261 (211–325) 4.5 (4.2–4.7)
Unknown 22 14.3 (12.6–15.4) 92.3 (89.1–93.9) 277 (181–315) 4.4 (4.0–4.7)
P = .430 P < .001 P = .682 P = .050
Period of cancer diagnosis (year)
1997–2004 90 13.4 (12.2–14.4) 95.1 (91.2–98.8) 262 (212–315) 4.3 (4.0–4.7)
2005–2008 91 13.8 (12.7–14.9) 91.8 (89.0–96.2) 274 (228–343) 4.4 (4.1–4.6)
2009–2015 79 14.0 (13.1–15.0) 93.8 (89.7–99.8) 236 (199–297) 4.6 (4.4–4.7)
P = .001† P = .858† P = .174† P = .020†
Cancer site
Oropharynx 153 13.8 (12.6–14.9) 92.5 (89.1–97.6) 264 (209–309) 4.4 (4.2–4.7)
Other 107 13.8 (12.6–14.5) 94.1 (91.6–99.5) 245 (206–325) 4.5 (4.1–4.7)
P = .871 P = .019 P = .621 P = .528
T
cT1-T2 61 14.0 (12.7–15.3) 92.4 (89.4–94.3) 257 (206–304) 4.5 (4.3–4.6)
cT3 88 14.0 (13.3–15.0) 94.2 (91.0–99.4) 253 (204–313) 4.5 (4.2–4.7)
cT4 111 13.2 (12.0–14.5) 93.9 (89.8–99.2) 263 (214–345) 4.4 (4.0–4.6)
P < .001† P = .178† P = .138† P = .127†
N
cN0 53 14.0 (13.1–15.2) 93.3 (89.4–99.3) 257 (207–300) 4.6 (4.3–4.8)
cN1 45 13.9 (12.7–14.5) 92.4 (90.0–96.9) 256 (220–310) 4.4 (4.1–4.7)
cN2-N3 162 13.6 (12.4–14.7) 93.8 (89.8–99.0) 260 (209–335) 4.4 (4.1–4.6)
P = .101† P = .558† P = .577† P = .042†
Stage
III 71 14.0 (13.1–15.0) 92.8 (89.9–99.3) 249 (207–301) 4.5 (4.2–4.7)
IVA-B 188 13.6 (12.4–14.7) 93.6 (89.8–98.7) 260 (210–336) 4.4 (4.1–4.6)
P = .028 P = .959 P = .285 P = .113
HPV status‡
Negative 63 13.3 (12.1–14.4) 92.6 (89.3–100.1) 260 (199–337) 4.4 (4.3–4.7)
Positive 54 14.5 (13.6–15.6) 90.9 (88.1–93.9) 235 (201–291) 4.6 (4.3–4.7)
Undetermined 36 12.9 (12.2–14.6) 95.8 (91.9–99.6) 288 (238–367) 4.1 (3.9–4.2)
P < .001 P = .003 P = .031 P < .001
*Differences across strata were evaluated through Kruskal-Wallis test;
†Test for trend using Jonckhere-Terpstra test;
‡On oropharyngeal squamous cell carcinomas only, based on p16 immunostaining.
c = clinical staging; Hb = hemoglobin; HPV = human papillomavirus; MCV = mean corpuscular volume; N = node; Q1-Q3 = interquartile ranges; T = tumor.
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specific and overall survival, independent of systemic
inflammation in colorectal cancers.11 The presence of a
host systemic inflammatory response, and red cell
markers of iron status are well documented to have a
negative prognostic impact.12
Serum albumin, one of the most commonly used bio-
markers to assess nutritional status, is usually
unchanged in the early stages of cancer. However as the
disease progresses, malnutrition and inflammation lead
to suppression of albumin synthesis and increased
albumin degradation, which may result in a significant
reduction in albumin level.13 Several albumin-based
markers, such as the Glasgow Prognostic Score, Advanced
Lung Cancer Inflammation Index,14 and Prognostic
Nutritional Index,15 have also been shown to correlate
with survival in various cancers, with decreased albumin
levels associated with shorter survival and increased can-
cer-related mortality.16
To date, the combined prognostic value of MCV,
hemoglobin (Hb), PLT, and albumin in HNSCC
Fig. 1 Kaplan–Meier estimates of progression-free survival and overall survival according to Hb and MCV levels. Normal Hb was defined as
≥12 g/dL for women and ≥13 g/dL for men.Hb = hemoglobin; MCV = mean corpuscular volume. [Color figure can be viewed in the online
issue, which is available at www.laryngoscope.com.]
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patients has not been reported. The aim of this study
was to evaluate the prognostic value of preoperative
MCV, Hb, PLT and albumin for patients who received




This is an international, multicenter retrospective
cohort study of patients with locoregionally advanced
HNSCC (stage III/IVA-B). Data for the present analysis
were derived from two cohorts: The first cohort included
170 patients diagnosed between 1997 and 2014 at the
University Hospital Cancer Centre of Treviso, Italy. The
second cohort included 90 patients diagnosed and treated
between 2008 and 2014 at the Queen Elizabeth Hospital
Birmingham, a large tertiary head and neck oncology cen-
ter in the United Kingdom. Consecutive patients were
included if they had stage III/ IVA-B disease at presenta-
tion and had completed organ preservation treatment
with concurrent platinum-based chemoradiotherapy with
curative intent at the time of data collection. In both
cohorts, diagnosis was confirmed histologically by tissue
biopsy, and anatomical (computed tomography/magnetic
resonance imaging) and functional (fluorodeoxyglucose/
positron electron tomography) imagining were obtained
as dictated by the clinical circumstances in order to stage
the cancer in accordance with the American Joint Com-
mittee on Cancer (7th edition) staging classification. As a
matter of course, all efforts are made to limit treatment
interruptions in order to complete treatment within
7 weeks. Before treatment, all patients were discussed at
the head and neck multidisciplinary team meeting of each
institute. Patients with previous malignancy, distant metas-
tasis, additional synchronous primary tumors, or who were
treated with up-front surgery were excluded, as were those
with a history of hematological conditions and those for
whom pretreatment blood test results were unavailable.
Data were retrospectively collected from case notes by
the clinical team on the following clinical parameters: age
at diagnosis, gender, smoking status, alcohol assumption,
cancer site (oral cavity, oropharynx, hypopharynx and lar-
ynx), clinical tumor-node-metastasis (cTNM) stage, human
papillomavirus (HPV) status (where relevant), treatment
protocol, recurrent tumor, and survival.
In both centers, HPV-status was determined by p16
immunostaining. p16 was scored positive if 70% or more
of malignant cells showed strong and diffuse nuclear and
cytoplasmic staining.
Pretreatment serum biochemical and hematological
indices (Hb, MCV, PLT and albumin), which were mea-
sured using standard protocols, were recorded.
Statistical Analyses
The study was designed to compare survival curves
through Cox-proportional hazard model. Considering the
retrospective nature of the study, sample size was deter-
mined by available data (n = 260), and a power analysis
was conducted. Assuming that 50% of patients die during
the study period, and fixing the a priori probabilities
α = 0.05 and β = 0.20 (power = 80%), the present sample
size allowed the detection of a hazard ratio (HR) ≥ 1.55
when the study population is split into two groups of
equal size, and a HR ≥ 1.62 when the study population is
split into two groups containing one-third and two-thirds
of the study population, respectively.
TABLE II.
Hazard Ratios* of PFS Event and Death, and Corresponding Confidence Intervals, According to Hemoglobin, MCV, Platelets and Albumin
Levels in the Discovery Cohort, in the Validation Cohort, and in Both Cohorts Combined.
Progression-Free Survival Overall Survival
Patients Events HR (95% CI) Bootstrap HR (95% CI) Events HR (95% CI) Bootstrap HR (95% CI)
Hemoglobin (g/dL)†
Normal 191 81 Reference Reference 67 Reference Reference
Low 69 59 2.86 (1.99–4.10) 3.08 (2.11–4.51) 58 3.29 (2.26–4.81) 3.62 (2.50–5.98)
MCV (fL)
<95.8 167 77 Reference Reference 71 Reference Reference
≥95.8 93 93 1.57 (1.10–2.24) 1.67 (1.18–2.55) 54 1.54 (1.06–2.24) 1.70 (1.11–2.66)
Platelets (103/mm3)
≥263 125 64 Reference Reference 59 Reference Reference
<263 135 76 1.18 (0.84–1.67) 1.10 (0.79–1.62) 66 1.05 (0.72–1.51) 0.97 (0.64–1.42)
Albumin (g/dL)
<4.4 76 42 Reference Reference 37 Reference Reference
≥4.4 114 52 0.91 (0.58–1.41) 0.86 (0.55–1.41) 47 1.06 (0.66–1.70) 0.94 (0.55–1.53)
*Estimated by Cox proportional hazard model conditioned on cohort and adjusted for gender, age, cancer site, stage and HPV status for oropharyngeal
cancer.
†Normal Hb was defined as ≥12 g/dL for women and ≥13 g/dL for men.
CI = confidence intervals; Hb = hemoglobin; HPV = human papillomavirus; HR = hazard ratios; MCV = mean corpuscular volume; PFS = progression-free
survival.
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Hb, MCV, PLT, and albumin were reported as
median values and interquartile ranges (Q1-Q3). Differ-
ences in biochemical values according to sociodemographic
and clinical characteristics were evaluated using the
Kruskal-Wallis test. Trends in median values across calen-
dar periods were tested using the Jonckheere-Terpstra
test. The impact of biochemical measurements on cancer
outcomes was investigated through survival analysis. For
each patient, time at risk was calculated from the date of
cancer diagnosis to death, cancer recurrence/progression
(for progression-free survival only), or last follow-up infor-
mation, truncating at 5 years. Progression-free survival
(PFS) and overall survival (OS) were estimated using the
Kaplan–Meier method, and differences in survival proba-
bilities between levels of biochemical measurements were
evaluated with the log-rank test.
To account for possible confounding factors, multivari-
able HRs and corresponding 95% confidence intervals were
calculated according to the Cox proportional hazards
model; conditioning on cohort; and adjusting for gender,
age, and covariates significantly associated with OS in a
multivariate model (i.e., cancer site, stage, and HPV status
for oropharyngeal cancer). Anemia was defined based on
World Health Organization guidelines17 as Hb < 12 g/dL
for women and Hb <13 g/dL for men. For MCV, platelets,
and albumin, optimal cutoffs were defined as the value
that maximizes the predictive value in overall survival, as
measured by Harrell’s c-index. These were 95.8 fL for
MCV, 263 103/mm3 for platelets, and 4.4 g/dL for albumin.
To avoid sparse data due to small sample size, the
analyses were conducted on both cohorts combined. Inter-
nal validation was conducted using the bootstrap method
with a total re-sampling number of 1 thousand.
Role of the Funding Source
There were no contributions to study design, data
collection, analysis and interpretation of data, writing of
the report, or the decision to submit the article for publi-
cation. There was no funding obtained for this study.
Ethical Considerations
The research protocol was conducted in compliance
with the Declaration of Helsinki (2008). This study was
observational and did not affect patient care in any way.
Data Availability Statement
The data that support the findings of this study are
available from the corresponding author upon reasonable
request.
RESULTS
Patient Characteristics and Pretreatment MCV
The sociodemographic and clinical characteristics of
the 260 patients enrolled for the study are summarized in
Table I, together with median values of biochemical mea-
surements. Overall, median preoperative Hb was 13.8 g/
dL, which was significantly lower in ever than in never
smokers (P = .031), in stage IV tumors than in stage III
(P = .028), and in HPV-positive than in HPV-negative oro-
pharyngeal cancers (P < .001). The median MCV was
93.1 fL, which was significantly lower in female than
male patients (P = .002), in never than ever smokers
(P < .001), in never than ever drinkers (P < .001), in oro-
pharyngeal cancer than other sites (P = .019), and in
HPV-positive than in HPV-negative oropharyngeal can-
cers (P = .003). No association emerged for PLT or albu-
min with any of the reported sociodemographic and
clinical characteristics.
Patients with normal pretreatment Hb levels had
better PFS and OS than anemic patients (Fig. 1), with a
5-year OS of 61.0% and 15.2%, respectively (P < .001).
Similarly, patients with MCV <95.8 fL had better onco-
logical outcomes than patients with MCV ≥ 95.8 fL, with
a 5-year OS of 53.9% and 38.9%, respectively (P = .002).
Fig. 2. Kaplan–Meier estimates of progression-free survival and
overall survival according to combined levels of Hb and MCV. Nor-
mal Hb was defined as ≥12 g/dL for women and ≥13 g/dL for men.
Follow-up was truncated at 5 years.Hb = hemoglobin; MCV = mean
corpuscular volume. [Color figure can be viewed in the online issue,
which is available at www.laryngoscope.com.]
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After adjustment for potential confounders, patients with
low Hb had a 3.3-fold higher risk of death (95% CI: 2.26–
4.81) than those with normal Hb (Table II). A similar
association was found between low Hb and PFS
(HR = 2.86; 95% CI: 1.99–4.10). Elevated MCV was also
associated with worse PFS (HR = 1.57; 95% CI: 1.10–
2.24) and OS (HR = 1.54; 95% CI: 1.06–2.24). No associa-
tions emerged for PLT or albumin. Further adjustment
for calendar period of cancer diagnosis or drinking habits
did not substantially change the results. All results were
confirmed by bootstrap validation.
We further investigated the interaction between Hb
and MCV levels. Interestingly, MCV seemed to play a
role in survival outcomes only in patients normal Hb
(Fig. 2). Indeed, in patients with normal Hb, high MCV
reduced 5-year PFS to 39.1% compared to 62.1% in
patients with low MCV (HR = 2.06; 95% CI: 1.27–3.34).
Similarly, in patients with normal Hb, 5-year OS was
65.1% and 52.9% in those with low and high MCV level,
respectively (HR = 1.78; 95% CI: 1.05–3.02). Conversely,
in patients with anemia, no significant differences in sur-
vival outcomes emerged according to MCV levels (Fig. 2).
The interaction between Hb and MCV was then ana-
lyzed separately by cancer site and stage (Fig. 3). Although
results should be interpreted with caution due to small
sample sizes in some subgroups, this analysis suggests
that elevated MCV did not have any impact on survival
outcomes in patients with anemia. Conversely, among
patients with normal Hb, elevated MCV level significantly
increased the HRs of both PFS events and death in stage
IV HNSCCs, but not in stage III cancers. Furthermore,
the increase in HRs for PFS and OS due to elevated MCV
was similar for all cancer sites, although the HR was sig-
nificant only among oropharyngeal cancers.
DISCUSSION
This represents the first study to investigate the
combined role of pretreatment MCV with Hb as prognos-
tic markers in HNSCC. Both anemia and macrocytosis
were associated with worse OS and PFS, with anemia
predicting a 3.3-fold higher risk of death than those with
normal Hb levels, and increased MCV predicting a 1.54-
fold higher risk of death than those with normal MCV.
Interestingly, elevated MCV was a prognostic maker of
poor PFS and OS in patients with normal Hb levels, who
are expected to have good prognosis according their Hb
level.
One possible explanation for these findings could be
that folate deficiency and macrocytosis are induced by
alcohol abuse or smoking, which themselves are notori-
ous risk factors for HNSCC. As previously shown in
esophageal squamous cell carcinoma, the risk of develop-
ing this cancer was increased in parallel with raised
MCV; and tobacco, alcohol, dietary habits, and aldehyde
dehydrogenase 2 were major determinants of MCV
changes.5 The association between higher MCV and poor
outcome may therefore be indicative that patients with
HNSCC who are exposed to ethanol have a poorer prog-
nosis than other HNSCC.18 Recently, alcohol consump-
tion was found to be strongly associated with poor
prognosis of HNSCC overall, with its impact being
higher in patients submitted to radiation treatment
compared to those receiving surgery.19 However, this
would not explain why the combination of macrocytosis
and anemia does not have an impact on survival.11
Moreover, in our study, the estimated HRs are indepen-
dent from tobacco smoking. If further adjusted for alco-
hol consumption, the magnitude of the effect was
similar. Therefore, we can conclude that the prognostic
Fig. 3. Hazard ratios and corresponding 95% confidence intervals for progression-free and overall survival according to combined levels of Hb
and MCV. HRs were adjusted for gender, age, cancer site, HPV status, and stage when appropriate. hb = Low Hb; HB = Normal Hb;
mcv = MCV < 95.8 fL; MCV = MCV ≥ 95.8 fL. Low Hb was defined as <12 g/dL for women and <13 g/dL for men.CI = confidence intervals; Hb
= hemoglobin; HPV = human papillomavirus; HR = hazard ratios; MCV = mean corpuscular volume.
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effect of MCV is independent from tobacco and alco-
hol use.
This could support the theory of the association
between anemia, systemic inflammation, and survival,
already widely studied in colorectal cancers.20 One mech-
anism linking systemic inflammation with anemia is the
action of proinflammatory cytokines, including IL-6 stim-
ulating the hepatic expression of hepcidin, which inhibits
the absorption of iron in the duodenum. Furthermore,
inflammation results in a limited availability of iron for
erythroid cells, leading to macrophage activation and
phagocytosis of erythrocytes.21 Finally, several cytokines
produced by the inflammatory process, including TNF-α
and IFNγ inhibit the synthesis of erythropoietin in the
kidney, leading to diminished erythropoiesis and
anemia.22
A recent study on colorectal cancer patients has
found that anemia is associated with poor cancer-specific
and overall survival regardless of MCV (and independent
of systemic inflammation).11 Our data on HNSCC support
this finding, with pretreatment anemia predicting a
poorer PFS and OS (P < .001).
MCV is not only an indicator of anemia but also a
marker of inflammation and endothelial function.23 Inter-
estingly, MCV may predict the efficacy of some chemo-
therapeutic agents such as 5-Fluorouracil (5-FU).3 This is
particularly interesting considering that our cohorts
included only patients who underwent organ preservation
protocol treatment. 5-FU inhibits tumor growth by block-
ing thymidylate synthase (TS), which is involved in DNA
synthesis. The high tumor expression of TS is generally
associated with a poor prognosis and with favorable
responses to 5-FU.24 Accordingly, a relatively high preop-
erative MCV might be associated with the corresponding
folate deficiency due to increased DNA synthesis in cases
in which the tumor expression of TS is high.
No association emerged for PLT or albumin with any
of the measured sociodemographic and clinical character-
istics or with survival. Nevertheless, recent studies have
proposed the hypothesis that activated platelets contrib-
ute to tumorigenesis and metastasis through direct cell–
cell interactions and the release of various lipid and pro-
tein mediators. Antiplatelet agents (aspirin and possibly
other antiplatelet agents) may slow down and/or prevent
the development and progression of cancer.25
Despite our negative findings for albumin, an associ-
ation between hypoalbuminemia and poor prognosis in
patients with cancer is well recognized.16 This could be
due to our choice of definition for normal albumin, with
the aim of maximizing the predictive value of overall sur-
vival (4.4 g/dL). If we had chosen the widely used defini-
tion used by other authors (< 3.5 g/dL), only three
patients would have met this criterion thus limiting the
consistency of the analysis. It is of interest that hypo-
albuminemia does not just reflect the nutritional status
but also the inflammatory response in cancer patients.
This reduction in circulating albumin concentration
reflects the increased demand for specific amino acids for
mediator and acute-phase protein synthesis and immune
and antioxidant defenses. Inflammation also promotes
the degradation of available body protein, including
albumin, and body cell mass.13 It is however important to
acknowledge that the low study power to detect small
associations should be noted when interpreting these
results.
This is the first report in the contemporary literature
investigating MCV with Hb as potential prognostic fac-
tors in curable HNSCC. The use of two cohorts from sepa-
rate centers improves the applicability of the findings to
the general population. The main limitation is deter-
mined by the fact that HPV-related HNSCC may have
very different biology to non-HPV related tumors, and the
MCV was lower in HPV-positive oropharyngeal carci-
noma than HPV-negative ones. Furthermore, patients
with HPV-related oropharyngeal carcinoma tend to be
younger than other HNSCC patients, with fewer com-
orbidities and other risk factors. Nonetheless, the inclu-
sion of HPV status as a covariate in the regression model
did not substantially modify the risk estimates,
supporting the fact that MCV is prognostic factor inde-
pendent from HPV status. A further limitation is the lack
of data on treatment interruption and thus treatment
duration. There is some evidence that in patients receiv-
ing concurrent chemoradiotherapy for HNSCC, prolonged
duration of treatment increases the risk of local failure.26
This is therefore a potential source of bias in the current
study; however, standard practice in both centers during
the study period was to limit pauses in treatment as
much as possible. Therefore, it is likely that the number
of patients with prolonged treatment times, and thus the
effect on the outcome, was negligible.
CONCLUSION
Pretreatment anemia is confirmed to adversely affect
OS and PFS in patients receiving concurrent
chemoradiotherapy with curable intent for locoregional
advanced HNSSC. In addition, our findings suggest that
high MCV could be used as a predictive marker of poor
prognosis in patients with normal Hb levels, which in
turn could facilitate the tailoring of frequency and inten-
sity of follow-up after treatment. Further studies are
required to validate these results and to clarify the mech-
anism underlying the association between anemia, mac-
rocytosis, and the prognosis of patients with HNSCC.
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